An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19 (INSIGHT 012)

This treatment study is a collaboration of INSIGHT and the Division of Clinical Research (DRC) at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).

This study will compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune Intravenous Immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed SARS-CoV-2 infection who do not require hospitalization.

For more details about the study, please go to ClinicalTrials.gov and the Clinical Trial Register